NEUROENDOCRINE A021602

Study #A021602

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)

Back To Clinical Trials